Skip to main content
. 2023 Apr 26;66(9):6414–6435. doi: 10.1021/acs.jmedchem.3c00541

Figure 1.

Figure 1

Key structures targeting BChE and/or CB2R. (a) Carbamate-based ChEIs; (b) benzimidazole CB2R agonist developed by AstraZeneca; and (c) selection of recently reported CB2R/BChE hybrid molecules.13−21